Zydus Lifesciences cash flow

Latest FY26

Cash from operations: ₹2,117cr−68.8% on FY25
Capital spending: ₹3,394cr+98.2% on FY25
Free cash flow: −₹1,277cr₹5,064 cr in FY25
Cash from financing: ₹5,997cr+195.3% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	1,408	916	764	723
	—	365	160	75.6	126
	—	−423	−185	−127	−75.7
	—	−1.2	−1.0	−1.3	−1.1
	—	−29.2	0.0	0.0	0.0
	—	−1,753	−138	0.0	0.0
	—	145	291	−148	284
	—	−2.3	−99.5	−54.3	−69.1
	—	0.0	0.0	29.2	−7.0
	—	−412	−445	−2.0	441
	—	−858	1,256	−747	−849
	—	−462	111	−144	146
	—	−795	98.6	−44.8	−171
	—	−96.3	511	67.1	197
	—	54.9	60.3	17.0	−22.9
	—	−54.0	16.7	20.7	−29.8
Cash from operating activities
	6,007	6,621	6,027	4,809	2,590
	—	−2,914	2,552	−295	691
	—	3,708	8,579	4,514	3,281
	—	1,591	1,802	1,286	592
	—	2,117	6,777	3,228	2,689
Cash from investing activities
	—	3,394	1,713	907	1,031
	—	24.9	51.4	23.7	39.4
	—	0.0	0.0	358	250
	—	0.0	0.0	408	2,298
	—	345	42.5	107	0.0
	—	112	216	55.0	40.0
	—	0.0	671	0.0	0.0
	—	0.0	18.5	0.0	0.0
	—	5,879	369	720	0.0
	—	0.0	75.6	−0.9	2.4
	—	73.2	0.0	0.0	0.0
	—	1.2	1.0	1.3	1.1
	—	427	182	127	76.5
	—	684	−5,970	0.0	0.0
	—	−8,296	−8,372	−1,475	1,171
Cash from financing activities
	—	0.0	0.0	725	863
	—	8,260	2,402	0.0	155
	—	968	0.0	393	3,302
	—	25.5	−4.2	−1.4	−3.3
	—	354	89.5	72.9	126
	—	1,106	303	621	267
	—	190	16.6	6.0	0.0
	—	5,997	2,031	−1,804	−4,400
	—	−182	435	−51.7	−540
	—	211	−21.4	−23.1	6.6
	—	28.4	414	−74.8	−534
	—	—	827	413	573
Reference items
	8,316	8,475	7,059	5,384	3,860
	29.1%	31.2%	30.4%	27.5%	22.4%
	−1,277	−1,277	5,064	2,321	1,658
	—	6,969	7,376	1,854	—
	−₹12.70	−₹12.70	₹50.34	₹23.07	₹16.48
	—	0.41×	1.45×	0.81×	1.29×
	—	1,591	1,802	1,286	592
	—	354	89.5	72.9	126

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ZYDUSLIFE₹1,175.50

Zydus Lifesciences Ltd.

· Pharma & Health

₹ CrorePeersSUNPHARMA DRREDDY CIPLA TORNTPHARM DIVISLAB MAXHEALTH APOLLOHOSP AUROPHARMAMcap ₹1.18L Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	722.7	764.1	915.8	1,408.0	—
+ Finance Costs	125.5	75.6	160.1	365.0	—
+ Interest Income	-75.7	-126.8	-185.2	-422.5	—
+ Dividend Income	-1.1	-1.3	-1.0	-1.2	—
+ Fair Value (Gains) / Losses	0.0	0.0	0.0	-29.2	—
+ Unrealised FX (Gain) / Loss	0.0	0.0	-137.9	-1,753.3	—
+ Other Non-cash Items	284.3	-148.3	291.1	144.8	—
+ Other — Cash Effects are Investing / Financing	-69.1	-54.3	-99.5	-2.3	—
+ Other Reconciling Items	-7.0	29.2	0.0	0.0	—
Changes in Working Capital
+ Inventories	440.7	-2.0	-444.9	-412.4	—
+ Trade Receivables — Current	-848.5	-747.2	1,255.8	-858.1	—
+ Other Current Assets	145.9	-144.2	110.9	-461.8	—
+ Trade Payables — Current	-170.8	-44.8	98.6	-795.1	—
+ Other Current Liabilities	196.9	67.1	511.1	-96.3	—
+ Provisions — Current	-22.9	17.0	60.3	54.9	—
+ Provisions — Non-current	-29.8	20.7	16.7	-54.0	—
Cash from Operating Activities
Profit Before Tax (per I/S)	2,589.7	4,808.9	6,026.7	6,621.1	6,007.1
+ Total Adjustments (incl. Working Capital)	691.1	-295.2	2,551.9	-2,913.5	—
Cash from Operations (pre-tax)	3,280.8	4,513.7	8,578.6	3,707.6	—
+ Income Taxes Paid	592.0	1,285.8	1,801.9	1,591.0	—
Cash from Operating Activities	2,688.8	3,227.9	6,776.7	2,116.6	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	1,030.9	906.6	1,712.6	3,394.0	—
+ Disp of Fixed Assets	39.4	23.7	51.4	24.9	—
+ Acq of Other Long-term Assets	250.2	357.8	0.0	0.0	—
+ Disp of Other Long-term Assets	2,297.7	407.7	0.0	0.0	—
+ Purchase of Investments (Equity / Debt)	0.0	106.7	42.5	345.2	—
+ Sale of Investments (Equity / Debt)	40.0	55.0	216.0	112.0	—
+ Acq of Interests in Joint Ventures	0.0	0.0	670.8	0.0	—
+ Disp of Interests in Joint Ventures	0.0	0.0	18.5	0.0	—
+ Acq of Subsidiaries / Businesses (net)	0.0	720.1	369.0	5,879.3	—
+ Loans & Advances Made	2.4	-0.9	75.6	0.0	—
+ Loans & Advances Repaid	0.0	0.0	0.0	73.2	—
+ Dividends Received — Investing	1.1	1.3	1.0	1.2	—
+ Interest Received — Investing	76.5	127.4	181.5	427.2	—
+ Other Inflows / (Outflows) — Investing	0.0	0.0	-5,970.2	683.9	—
Cash from Investing Activities	1,171.2	-1,475.2	-8,372.3	-8,296.1	—
Cash from Financing Activities
+ Buyback / Redemption of Own Shares	863.2	725.0	0.0	0.0	—
+ Proceeds from Borrowings	155.2	0.0	2,402.0	8,260.2	—
+ Repayment of Borrowings	3,302.4	392.9	0.0	967.9	—
+ Payment of Lease Liabilities	-3.3	-1.4	-4.2	25.5	—
+ Interest Paid	126.2	72.9	89.5	353.6	—
+ Dividends Paid	267.1	621.0	302.5	1,106.3	—
+ Other Inflows / (Outflows) — Financing	0.0	6.0	16.6	190.2	—
Cash from Financing Activities	-4,400.4	-1,804.4	2,030.8	5,997.1	—
Net Changes in Cash (pre-FX)	-540.4	-51.7	435.2	-182.4	—
+ Effect of FX Rate Changes on Cash	6.6	-23.1	-21.4	210.8	—
Net Changes in Cash	-533.8	-74.8	413.8	28.4	—
Closing Cash	573.1	413.0	826.8	—	—
Reference Items
EBITDA	3,859.9	5,384.3	7,058.5	8,475.1	8,316.0
EBITDA Margin %	22.39	27.54	30.37	31.22	29.09
Free Cash Flow (CFO − Capex)	1,657.9	2,321.3	5,064.1	-1,277.4	-1,277.4
Free Cash Flow to Equity	—	1,853.8	7,375.5	6,969.0	—
Free Cash Flow per Basic Share	16.48	23.07	50.34	-12.70	-12.70
Cash Flow to Net Income	1.29	0.81	1.45	0.41	—
Cash Paid for Taxes	592.0	1,285.8	1,801.9	1,591.0	—
Cash Paid for Interest	126.2	72.9	89.5	353.6	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.